Bioretec entered into a distribution agreement with AMI Medical Technologies. Under the 5-year exclusive agreement, AMI Medical Technologies will distribute, promote and sell Bioretec’s bioresorbable Activa implants in Israel. Bioretec’s Activa portfolio, already sold in about 40 countries, comprises biopolymer implants for pediatric, trauma and sports surgery.
“I’m pleased to announce the distribution agreement with AMI Medical Technologies and expanding to one of the most significant markets for orthopedic devices in the fast-growing Middle East and Africa markets. Together with AMI Medical Technologies, we are committed to raising healthcare standards in Israel by introducing patient-friendly and healthcare cost-reducing medical technology. As Activa implants are bioresorbable, they eliminate the complications and secondary removal operations associated with permanent metallic implants. Our products bring significant benefits to both the patient and the healthcare system,” said Timo Lehtonen, CEO of Bioretec.
Bioretec entered into a distribution agreement with AMI Medical Technologies. Under the 5-year exclusive agreement, AMI Medical Technologies will distribute, promote and sell Bioretec's bioresorbable Activa implants in Israel. Bioretec's Activa portfolio, already sold in about 40 countries, comprises biopolymer implants for pediatric, trauma and...
Bioretec entered into a distribution agreement with AMI Medical Technologies. Under the 5-year exclusive agreement, AMI Medical Technologies will distribute, promote and sell Bioretec’s bioresorbable Activa implants in Israel. Bioretec’s Activa portfolio, already sold in about 40 countries, comprises biopolymer implants for pediatric, trauma and sports surgery.
“I’m pleased to announce the distribution agreement with AMI Medical Technologies and expanding to one of the most significant markets for orthopedic devices in the fast-growing Middle East and Africa markets. Together with AMI Medical Technologies, we are committed to raising healthcare standards in Israel by introducing patient-friendly and healthcare cost-reducing medical technology. As Activa implants are bioresorbable, they eliminate the complications and secondary removal operations associated with permanent metallic implants. Our products bring significant benefits to both the patient and the healthcare system,” said Timo Lehtonen, CEO of Bioretec.
Copy to clipboard 
